Wells Fargo & Company Allogene Therapeutics, Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 55,204 shares of ALLO stock, worth $123,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,204

Previous 54,170 1.91%

Holding current value

$123,656

Previous $173,000 42.2%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.92 - $5.63 $3,019 - $5,821	1,034 Added 1.91%	55,204 $246,000
Q4 2023 Feb 09, 2024	SELL	$2.28 - $3.5 $261,734 - $401,786	-114,796 Reduced 67.94%	54,170 $173,000
Q3 2023 Nov 13, 2023	BUY	$3.17 - $5.96 $10,109 - $19,006	3,189 Added 1.92%	168,966 $535,000
Q2 2023 Aug 15, 2023	BUY	$4.53 - $6.74 $152,887 - $227,475	33,750 Added 25.56%	165,777 $823,000
Q1 2023 May 12, 2023	BUY	$4.92 - $8.21 $623,398 - $1.04 Million	126,707 Added 2381.71%	132,027 $652,000

Q4 2022 Feb 13, 2023	SELL	$5.62 - $11.11 $10,537 - $20,831	-1,875 Reduced 26.06%	5,320 $33,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $2,084 - $3,490	202 Added 2.89%	7,195 $78,000
Q2 2022 Aug 12, 2022	SELL	$6.78 - $12.28 $42,178 - $76,393	-6,221 Reduced 47.08%	6,993 $79,000
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $196,429 - $392,601	-25,677 Reduced 66.02%	13,214 $121,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $242,327 - $452,541	18,456 Added 90.32%	38,891 $580,000
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $202,641 - $266,587	9,645 Added 89.39%	20,435 $526,000
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $128,443 - $195,754	5,468 Added 102.74%	10,790 $281,000
Q1 2021 May 13, 2021	SELL	$25.79 - $39.02 $764,905 - $1.16 Million	-29,659 Reduced 84.79%	5,322 $187,000
Q4 2020 Feb 09, 2021	BUY	$25.24 - $43.45 $147,754 - $254,356	5,854 Added 20.1%	34,981 $883,000
Q3 2020 Nov 05, 2020	BUY	$32.38 - $44.96 $281,544 - $390,927	8,695 Added 42.56%	29,127 $1.1 Million
Q2 2020 Aug 13, 2020	SELL	$18.39 - $54.04 $151,993 - $446,640	-8,265 Reduced 28.8%	20,432 $874,000
Q1 2020 May 14, 2020	BUY	$18.22 - $28.25 $522,859 - $810,690	28,697 New	28,697 $558,000

Others Institutions Holding ALLO

# of Institutions

163

Shares Held

106M

Call Options Held

97.5K

Put Options Held

45.6K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $322M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Allogene Therapeutics, Inc. Transaction History